Immunotherapy utilization in stage IIIA melanoma: less may be more

Immunotherapy utilization in stage IIIA melanoma: less may be more

BackgroundImmunotherapy agents are approved for adjuvant treatment of stage III melanoma; however, evidence for survival benefit in early stage III disease is lacking. Current guidelines for adjuvant immunotherapy utilization in stage IIIA rely on clinician judgment, creating an opportunity for sign...

Full description

Bibliographic Details
Main Authors: Alexander E. Frey, Daniel M. Kerekes, Sajid A. Khan, Thuy T. Tran, Harriet M. Kluger, James E. Clune, Stephan Ariyan, Mario Sznol, Jeffrey J. Ishizuka, Kelly L. Olino
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-02-01
Series:Frontiers in Oncology
Subjects:
melanoma
immunotherapy
skin cancer
guidelines
treatment
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2024.1336441/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2024.1336441/full

Similar Items